For citations:
Volkova M.I., Kalpinskiy A.S., Goncharova О.A., Menshikov К.V., Stativko O.A., Karabina E.V., Dergunov A.S., Polshina N.I., Aleksandrova E.N., Lebedinets A.A., Panov A.K., Sultanbaev A.V., Usynin E.A., Volkonsky M.V., Mikhalyuk V.V., Zukov R.A., Anzhiganova Yu.V., Gusniev M.A., Igumnova E.N., Kuzmicheva S.V., Pokataev I.A., Olshanskaya A.S., Pervakova N.I., Parsadanova E.L., Sannikova T.A., Bystrov A.A., Dubovichenko D.M., Mukhitova M.R., Chubenko V.A., Shkret K.A., Gorshenina M.N., Semenov A.V., Davlatova M.K., Kosareva A.E., Lutoshkina O.A., Maslova O.A., Makhnutina M.V., Mishina A.V., Murzalina M.Zh., Podyacheva O.A., Kalinin S.A., Mailyan O.A., Safarova A.R., Semenova K.O., Strokova M.A., Urashkina E.Yu., Shmygina O.S., Novikova O.Yu. Efficacy of the combination of lenvatinib with pembrolizumab in patients with advanced renal cell carcinoma. Cancer Urology. 2024;20(3):33-48. (In Russ.) https://doi.org/10.17650/1726-9776-2024-20-3-33-48
Email this article 